Advances in the medical management of Cushing's syndrome

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Management of Cushing's syndrome, that is, excess cortisol secretion, has undergone considerable advances since the pioneering studies by Harvey Cushing. Surgery is clearly first choice for all etiologies of Cushing's syndrome, and medical therapy is largely administered in the interim between other therapeutic options. The limited use of medical therapy is a consequence of the lack of a truly efficacious compound to restrain adrenocorticotrophic hormone or cortisol secretion, but this will hopefully change in the near future as molecules developed over the past few years are tested. Conclusion: This paper illustrates present and perspective medical treatments for Cushing's syndrome.

Original languageEnglish
Pages (from-to)2423-2433
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number14
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Cushing Syndrome
Hydrocortisone
Adrenocorticotropic Hormone
Therapeutics

Keywords

  • ACTH
  • Bromocriptine
  • Cabergoline
  • Cortisol
  • Cushing's syndrome
  • Ketoconazole
  • Metyrapone
  • Mitotane
  • Pasireotide
  • Retinoic acid
  • Somatostatin
  • Somatostatin analogues
  • Steroidogenesis inhibitors
  • Thiazolidinediones

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Advances in the medical management of Cushing's syndrome. / Giraldi, Francesca Pecori; Cavagnini, Francesco.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 14, 10.2008, p. 2423-2433.

Research output: Contribution to journalArticle

@article{d921c1c0009049dcae9ea3c57fae9f22,
title = "Advances in the medical management of Cushing's syndrome",
abstract = "Background: Management of Cushing's syndrome, that is, excess cortisol secretion, has undergone considerable advances since the pioneering studies by Harvey Cushing. Surgery is clearly first choice for all etiologies of Cushing's syndrome, and medical therapy is largely administered in the interim between other therapeutic options. The limited use of medical therapy is a consequence of the lack of a truly efficacious compound to restrain adrenocorticotrophic hormone or cortisol secretion, but this will hopefully change in the near future as molecules developed over the past few years are tested. Conclusion: This paper illustrates present and perspective medical treatments for Cushing's syndrome.",
keywords = "ACTH, Bromocriptine, Cabergoline, Cortisol, Cushing's syndrome, Ketoconazole, Metyrapone, Mitotane, Pasireotide, Retinoic acid, Somatostatin, Somatostatin analogues, Steroidogenesis inhibitors, Thiazolidinediones",
author = "Giraldi, {Francesca Pecori} and Francesco Cavagnini",
year = "2008",
month = "10",
doi = "10.1517/14656566.9.14.2423",
language = "English",
volume = "9",
pages = "2423--2433",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "14",

}

TY - JOUR

T1 - Advances in the medical management of Cushing's syndrome

AU - Giraldi, Francesca Pecori

AU - Cavagnini, Francesco

PY - 2008/10

Y1 - 2008/10

N2 - Background: Management of Cushing's syndrome, that is, excess cortisol secretion, has undergone considerable advances since the pioneering studies by Harvey Cushing. Surgery is clearly first choice for all etiologies of Cushing's syndrome, and medical therapy is largely administered in the interim between other therapeutic options. The limited use of medical therapy is a consequence of the lack of a truly efficacious compound to restrain adrenocorticotrophic hormone or cortisol secretion, but this will hopefully change in the near future as molecules developed over the past few years are tested. Conclusion: This paper illustrates present and perspective medical treatments for Cushing's syndrome.

AB - Background: Management of Cushing's syndrome, that is, excess cortisol secretion, has undergone considerable advances since the pioneering studies by Harvey Cushing. Surgery is clearly first choice for all etiologies of Cushing's syndrome, and medical therapy is largely administered in the interim between other therapeutic options. The limited use of medical therapy is a consequence of the lack of a truly efficacious compound to restrain adrenocorticotrophic hormone or cortisol secretion, but this will hopefully change in the near future as molecules developed over the past few years are tested. Conclusion: This paper illustrates present and perspective medical treatments for Cushing's syndrome.

KW - ACTH

KW - Bromocriptine

KW - Cabergoline

KW - Cortisol

KW - Cushing's syndrome

KW - Ketoconazole

KW - Metyrapone

KW - Mitotane

KW - Pasireotide

KW - Retinoic acid

KW - Somatostatin

KW - Somatostatin analogues

KW - Steroidogenesis inhibitors

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=54349110087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349110087&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.14.2423

DO - 10.1517/14656566.9.14.2423

M3 - Article

VL - 9

SP - 2423

EP - 2433

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 14

ER -